Bausch Health and Solta Medical announced the approval of Thermage FLX and the TR-4 Return Pad by China’s National Medical Products Administration. The TR-4 Return Pad is not approved for use by the U.S. Food & Drug Administration. Thermage is a non-invasive treatment that uses radiofrequency technology to help tighten and improve the smoothness and texture of the skin’s surface to optimize a patient’s appearance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BHC:
- Bausch Health reports Court of Appeals heard oral arguments on patent dispute
- Bausch Health put volume heavy and directionally bearish
- Bausch Health Companies (TSE:BHC) Surges after New Tests
- Bausch Health: Phase 2 study of Amiselimod meets primary, secondary endpoints
- Bausch Health announces DUOBRII availability through Quebec drug plan